Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 2
2011 1
2012 2
2013 1
2014 1
2016 1
2017 1
2019 2
2020 6
2021 3
2022 6
2023 5
2024 3
2025 5
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
The Impact of Celiprolol in Vascular Ehlers-Danlos Syndrome: A Systematic Review of Current Evidence.
Saputra PBT, Widiarti W, Siahaan PP, Putra RM, Putranto JNE, Budiarto RM, Luthfah N, Multazam CECZ, D'Oria M, Alkaff FF. Saputra PBT, et al. Med Sci (Basel). 2025 Jun 9;13(2):74. doi: 10.3390/medsci13020074. Med Sci (Basel). 2025. PMID: 40559232 Free PMC article.
OBJECTIVES: Ehlers-Danlos syndrome (EDS) is a group of connective tissue disorders characterized by mutations affecting collagen and extracellular matrix proteins. ...Limited strategies for treating vEDS are prompting exploration for alternatives such as celiprol …
OBJECTIVES: Ehlers-Danlos syndrome (EDS) is a group of connective tissue disorders characterized by mutations affecting collag …
Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome.
Baderkhan H, Wanhainen A, Stenborg A, Stattin EL, Björck M. Baderkhan H, et al. Eur J Vasc Endovasc Surg. 2021 Feb;61(2):326-331. doi: 10.1016/j.ejvs.2020.10.020. Epub 2020 Nov 20. Eur J Vasc Endovasc Surg. 2021. PMID: 33223285 Free article.
OBJECTIVE: Vascular Ehlers-Danlos syndrome (vEDS) is a rare monogenetic disease caused by pathogenic variants in procollagen 3A1. ...A randomised controlled trial, the Beta-Blockers in Ehlers-Danlos Syndrome Treatment (BBEST) trial, reported a s …
OBJECTIVE: Vascular Ehlers-Danlos syndrome (vEDS) is a rare monogenetic disease caused by pathogenic variants in procol …
Efficacy of Irbesartan in Celiprolol-Treated Patients With Vascular Ehlers-Danlos Syndrome.
Jeunemaitre X, Mousseaux E, Frank M, Adham S, Pitocco F, Billon C, Ben Yakhlef M, El Hachmi M, Bura-Rivière A, Lapébie FX, Le Hello C, Laneelle D, Seinturier C, Dieterich K, Lambert M, Dupuis-Girod S, Zuily S, Bal-Theoleyre L, Boulon C, Henneton P, Lu E, Denarié N, Boutouyrie P, Mirault T, Chatellier G, Azizi M. Jeunemaitre X, et al. Circulation. 2025 Mar 11;151(10):686-695. doi: 10.1161/CIRCULATIONAHA.124.072849. Epub 2025 Feb 5. Circulation. 2025. PMID: 39906986 Clinical Trial.
BACKGROUND: Vascular Ehlers-Danlos syndrome is a rare genetic disorder characterized by defective type III collagen and a high risk of arterial morbidity and mortality. ...CONCLUSIONS: Compared with placebo, irbesartan reduced the risk of severe symptomatic a …
BACKGROUND: Vascular Ehlers-Danlos syndrome is a rare genetic disorder characterized by defective type III collagen and …
[Vascular Ehlers-Danlos syndrome].
Perdu J, Boutouyrie P, Lahlou-Laforêt K, Khau Van Kien P, Denarié N, Mousseaux E, Sapoval M, Julia P, Zinzindohoué F, Touraine P, Dumez Y, Trystram D, Vignal-Clermont C, Gimenez-Roqueplo AP, Jeunemaitre X, Fiessinger JN. Perdu J, et al. Presse Med. 2006 Dec;35(12 Pt 2):1864-75. doi: 10.1016/s0755-4982(06)74919-3. Presse Med. 2006. PMID: 17159712 Review. French.
The vascular type of Ehlers-Danlos syndrome (EDS) is a rare genetic disease transmitted as an autosomal dominant trait. ...Psychological treatment and support of patients and their families is essential, to help them both to live with their disease and to dea …
The vascular type of Ehlers-Danlos syndrome (EDS) is a rare genetic disease transmitted as an autosomal dominant trait. …
Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study.
Frank M, Adham S, Seigle S, Legrand A, Mirault T, Henneton P, Albuisson J, Denarié N, Mazzella JM, Mousseaux E, Messas E, Boutouyrie P, Jeunemaitre X. Frank M, et al. J Am Coll Cardiol. 2019 Apr 23;73(15):1948-1957. doi: 10.1016/j.jacc.2019.01.058. J Am Coll Cardiol. 2019. PMID: 30999998 Free article.
BACKGROUND: Vascular Ehlers-Danlos syndrome (vEDS) is a rare genetic connective tissue disorder secondary to pathogenic variants within the COL3A1 gene, resulting in exceptional arterial and organ fragility and premature death. ...Patients treated with cel …
BACKGROUND: Vascular Ehlers-Danlos syndrome (vEDS) is a rare genetic connective tissue disorder secondary to pathogenic …
An old drug for a rare disease: The example of celiprolol for vascular Ehlers-Danlos syndrome.
Boutouyrie P. Boutouyrie P. Therapie. 2020 Apr;75(2):175-181. doi: 10.1016/j.therap.2020.02.009. Epub 2020 Feb 13. Therapie. 2020. PMID: 32127191 Review. French.
Vascular Ehlers-Danlos syndrome (OMIM 130050, 1/150,000 birth) is caused by mutations in collagen 3A1 gene. ...Celiprolol is unavailable in the USA. The ACER Therapeutics company applied for new drug application (NDA) to the Food and Drug Administratio …
Vascular Ehlers-Danlos syndrome (OMIM 130050, 1/150,000 birth) is caused by mutations in collagen 3A1 gene. ...Celip …
Despite celiprolol therapy, patients with vascular Ehlers-Danlos syndrome remain at risk of vascular events: A 12-year experience in an Italian referral center.
Buso G, Paini A, Agabiti-Rosei C, De Ciuceis C, Bertacchini F, Stassaldi D, Salvetti M, Ritelli M, Venturini M, Colombi M, Muiesan ML. Buso G, et al. Vasc Med. 2024 Jun;29(3):265-273. doi: 10.1177/1358863X231215330. Epub 2023 Dec 16. Vasc Med. 2024. PMID: 38102934
BACKGROUND: Vascular Ehlers-Danlos syndrome (vEDS) is an inherited connective tissue disorder characterized by arterial fragility. Celiprolol has been suggested to significantly reduce rates of vascular events in this setting, though real-world …
BACKGROUND: Vascular Ehlers-Danlos syndrome (vEDS) is an inherited connective tissue disorder characterized by arterial …
Current Evidence and Future Perspectives in the Medical Management of Vascular Ehlers-Danlos Syndrome: Focus on Vascular Prevention.
Buso G, Corvini F, Fusco EM, Messina M, Cherubini F, Laera N, Paini A, Salvetti M, De Ciuceis C, Ritelli M, Venturini M, Chiarelli N, Colombi M, Muiesan ML. Buso G, et al. J Clin Med. 2024 Jul 21;13(14):4255. doi: 10.3390/jcm13144255. J Clin Med. 2024. PMID: 39064294 Free PMC article. Review.
Vascular Ehlers-Danlos syndrome (vEDS) is a rare autosomal dominant connective tissue disease resulting from pathogenic variants in the collagen type III alpha 1 chain (COL3A1) gene, encoding type III procollagen. ...Increasing use of drugs acting on the card …
Vascular Ehlers-Danlos syndrome (vEDS) is a rare autosomal dominant connective tissue disease resulting from pathogenic …
37 results